Heart failure mbbs neet pg full explanation

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

Reading File

I now have comprehensive content from multiple authoritative textbooks. Let me compile the full NEET PG / MBBS explanation.

❤️ Heart Failure - Complete NEET PG / MBBS Explanation

Sources: Goldman-Cecil Medicine, Robbins & Kumar Basic Pathology, Braunwald's Heart Disease, Lippincott Pharmacology, Goodman & Gilman's

1. DEFINITION

Heart failure (HF) is a clinical syndrome in which the heart is unable to pump sufficient blood to meet the body's metabolic demands, or can do so only at the cost of elevated filling pressures. It is NOT a single disease but the end result of many cardiac conditions.

Systolic HF (HFrEF): Reduced ejection fraction (EF <40%) - impaired contractility
Diastolic HF (HFpEF): Preserved EF (>50%) - impaired relaxation/filling
HFmrEF: Mid-range EF (40-50%)

Nearly half of all HF patients have preserved EF. Mortality is similar in both HFrEF and HFpEF (~50% within 5 years of diagnosis). - Goldman-Cecil Medicine

2. ETIOLOGY / CAUSES

Category	Examples
Most common (70%)	Coronary artery disease / prior MI
Hypertension	Pressure overload causing LVH
Valvular disease	Aortic stenosis, mitral regurgitation
Cardiomyopathy	Dilated, hypertrophic, restrictive
Metabolic	Diabetes, obesity, metabolic syndrome
Toxins	Alcohol, chemotherapy (anthracyclines)
Infections	Myocarditis (Coxsackie B), Chagas disease
Infiltrative	Amyloidosis, sarcoidosis, hemochromatosis
Volume overload	AV fistulae, severe anemia, thyrotoxicosis

Mnemonic for causes: HIDE CAT - Hypertension, IHD, Dilated cardiomyopathy, Endocarditis/valvular, Cardiomyopathy (restrictive), Arrhythmias, Thyrotoxicosis

3. PATHOPHYSIOLOGY

Sequence of Events

Myocardial injury → ↓ Cardiac Output → Compensatory mechanisms → Decompensation

Compensatory Mechanisms (Initially Helpful, Eventually Harmful)

A. Frank-Starling Mechanism

↓ CO → ↑ venous return → ↑ preload → ↑ sarcomere stretch → ↑ contractility
Helps short term; long term causes ventricular dilation

B. Neurohormonal Activation (KEY for NEET PG)

System	Effect	Long-term consequence
Sympathetic NS	↑ HR, ↑ contractility, vasoconstriction	Norepinephrine toxic to myocytes; ↓ β-receptor density
RAAS	↑ Angiotensin II → vasoconstriction; Aldosterone → Na+/H2O retention	Maladaptive remodeling, fibrosis
ADH/Vasopressin	V1: vasoconstriction; V2: free water retention	Hyponatremia, volume overload
Endothelin	Prolonged vasoconstriction, ↓ GFR, pulmonary arteriolar constriction	Worsening HF
BNP/ANP (counterregulatory)	Vasodilation, natriuresis, diuresis	Marker of severity; elevated BNP = poor prognosis

"The sympathetic nervous system and RAAS are co-regulated, such that increased activity of each pathway stimulates a simultaneous increase in the other." - Goldman-Cecil Medicine

C. Ventricular Remodeling

Pathological hypertrophy + chamber dilation
Eccentric hypertrophy (volume overload - sarcomeres in series)
Concentric hypertrophy (pressure overload - sarcomeres in parallel)
Progressive → further LV dysfunction → spiral of worsening

D. Calcium Cycling Abnormality

Abnormal ryanodine receptors → diastolic Ca²⁺ leak from sarcoplasmic reticulum
Loss of SERCA2a function → impaired Ca²⁺ reuptake → diastolic dysfunction
Reduced Ca²⁺ stores → impaired systolic contraction

E. Cardiorenal Interaction

↓ cardiac output → ↓ renal perfusion + passive venous congestion → ↓ GFR
Worsening renal function → further Na+ and water retention → vicious cycle

4. CLASSIFICATION

A. ACC/AHA Staging (Progression-Based - NEET HIGH YIELD)

Stage	Description	Example
A	At risk, NO structural disease	HTN, DM, obesity, family history
B	Structural disease, NO symptoms	Previous MI, LVH, asymptomatic LV dysfunction
C	Structural disease WITH current or prior symptoms	Breathlessness, fatigue, reduced exercise tolerance
D	Refractory HF requiring specialized interventions	Recurrently hospitalized, symptoms at rest

KEY: Stage A and B = prevent progression. Stage C and D = treat symptoms and improve survival.

B. NYHA Functional Classification (Symptom-Based - HIGH YIELD)

Class	Description
I	No symptoms with ordinary activity
II	Slight limitation; symptoms with moderate exertion
III	Marked limitation; symptoms with minimal exertion
IV	Symptoms at rest; unable to carry out any activity

Remember: ACC/AHA stages are unidirectional (can't go back from C to B). NYHA classes are dynamic (can improve with treatment).

C. By Ejection Fraction

Type	EF	Key Feature
HFrEF	<40%	Systolic dysfunction; responds to most drugs
HFmrEF	40-50%	Intermediate; heterogeneous
HFpEF	>50%	Diastolic dysfunction; older, female, HTN

5. MORPHOLOGY / PATHOLOGY (Robbins - HIGH YIELD)

Left-Sided Heart Failure

Heart:

LV usually hypertrophied and dilated
LV dilation → functional mitral regurgitation → left atrial enlargement → atrial fibrillation
Microscopy: myocyte hypertrophy + interstitial fibrosis

Lungs (MOST IMPORTANT):

Acute: pulmonary edema - heavy, wet lungs; perivascular/interstitial transudates
Chronic: "Heart failure cells" = hemosiderin-laden alveolar macrophages (RBCs extravasate → phagocytosed → hemosiderin deposition)
Pleural effusion (from increased hydrostatic pressure in visceral pleural venules)

Right-Sided Heart Failure

Liver:

Congestive hepatomegaly
"Nutmeg liver" - congested centrilobular areas + paler peripheral parenchyma on cut section
Severe chronic: Cardiac cirrhosis (centrilobular fibrosis)

Spleen: Congestive splenomegaly

Other: Peripheral pitting edema (dependent), ascites, pleural effusion, pericardial effusion

6. CLINICAL FEATURES

Left Heart Failure (Pulmonary Congestion + Low Output)

Symptom	Mechanism
Dyspnea on exertion (earliest)	↑ pulmonary venous pressure → pulmonary edema
Orthopnea	Recumbent position → ↑ venous return → ↑ pulmonary congestion; relieved by sitting up
PND (paroxysmal nocturnal dyspnea)	Awakens from sleep; dramatic breathlessness/suffocation
Cardiac asthma	Wheeze from bronchospasm due to edema
Pink frothy sputum	Acute pulmonary edema
Fatigue/exercise intolerance	Low cardiac output
Nocturia	Fluid redistribution when recumbent at night
Cheyne-Stokes respiration	Reduced cerebral perfusion

Signs:

Elevated JVP (when biventricular)
3rd heart sound (S3) - gallop = PATHOGNOMONIC of HF (ventricular overload)
4th heart sound (S4) - non-compliant, stiff ventricle
Displaced/laterally displaced apex
Bilateral basal crepitations (crackles)
Pulsus alternans (alternating strong/weak pulse in severe LV failure)

Right Heart Failure (Systemic Congestion)

Raised JVP (jugular venous pressure) - most important sign
Hepatomegaly (tender, pulsatile)
Peripheral pitting edema (ankle → thigh → sacral in bedridden)
Ascites
Pleural effusion (more right-sided)
Kussmaul's sign (JVP rises on inspiration) in constrictive pericarditis/RV infarct

7. INVESTIGATIONS

Biomarkers (HIGH YIELD)

BNP (B-type Natriuretic Peptide) and NT-proBNP: Released from ventricular myocytes in response to wall stretch
- BNP >100 pg/mL = HF likely
- BNP <35 pg/mL = HF unlikely
- Used for diagnosis AND prognosis; ↑ BNP = worse outcome
- Elevated in ALL types of HF

Imaging

CXR: Cardiomegaly, pulmonary venous congestion, Kerley B lines, bat-wing perihilar edema, pleural effusion
Echo (2D Echo + Doppler): Gold standard - assesses EF, wall motion, valves, filling pressures
- EF <40% = HFrEF
- Tissue Doppler for diastolic function

ECG

May show LVH, Q waves (prior MI), LBBB, AF (common comorbidity)
LBBB with EF <35% = candidate for CRT (cardiac resynchronization therapy)

Others

Serum electrolytes, creatinine (renal function monitoring)
Thyroid function (rule out thyrotoxicosis)
CBC (anemia can worsen HF)
Coronary angiography (if ischemic etiology suspected)

8. TREATMENT

Non-Pharmacological

Salt restriction (<2g/day sodium)
Fluid restriction in advanced HF
Daily weight monitoring (if weight ↑ >1.5-2 kg over 2 days → adjust diuretic)
Regular aerobic exercise (once stable)
Vaccination (influenza, pneumococcal)
Avoid NSAIDs, verapamil/diltiazem (negative inotropes)

Pharmacological Treatment of HFrEF (EF <40%) - NEET MEGA HIGH YIELD

The "Fantastic Four" / GDMT (Guideline-Directed Medical Therapy):

Drug Class	Examples	Mechanism	Benefit
ARNI (first-line over ACEi)	Sacubitril/valsartan (Entresto)	Neprilysin inhibitor + ARB → ↑ BNP → vasodilation, natriuresis	Reduces mortality >ACEi
ACE Inhibitor	Ramipril, Enalapril, Lisinopril	Blocks angiotensin II, ↓ aldosterone	Reduces mortality, prevents remodeling
ARB	Valsartan, Candesartan	If ACEi intolerant (cough)	Similar to ACEi
β-Blocker	Carvedilol, Bisoprolol, Metoprolol succinate	Blocks SNS activation	Reduces mortality, ↑ EF
MRA (Aldosterone antagonist)	Spironolactone, Eplerenone	Block aldosterone → ↓ Na+ retention, ↓ fibrosis	Reduces mortality; watch K+
SGLT2 inhibitor	Dapagliflozin, Empagliflozin	Glucosuria → ↓ preload, cardioprotective	Newest pillar; reduces HF hospitalizations

Diuretics (symptom relief - do NOT improve mortality):

Loop diuretics: Furosemide - first-line for volume overload
Thiazides: Added in resistant cases
Combination (loop + thiazide) in stage D

Other drugs:

Ivabradine: If HR >70 bpm in sinus rhythm despite max β-blocker; inhibits If (funny current) in SA node
Digoxin: Rate control in AF with HF; modest symptom benefit (no mortality benefit); narrow therapeutic index - watch toxicity
Hydralazine + Isosorbide dinitrate: For patients who cannot tolerate ACEi/ARB/ARNI (especially in renal failure or African Americans)

Device Therapy

ICD (Implantable Cardioverter Defibrillator): EF ≤35%, NYHA II-III, on optimal medical therapy - prevents sudden cardiac death
CRT (Cardiac Resynchronization Therapy/Biventricular pacemaker): EF ≤35% + LBBB + QRS ≥150ms - resynchronizes LV contraction
CRT-D: Combined CRT + ICD

Advanced/Stage D HF

LVAD (Left Ventricular Assist Device): Bridge to transplant or destination therapy
Heart Transplantation: Gold standard for eligible patients

HFpEF Treatment

Currently no therapy proven to reduce mortality in HFpEF
Treat underlying cause (HTN, AF, obesity)
Diuretics for symptom relief
SGLT2 inhibitors (empagliflozin, dapagliflozin) - now shown to reduce HF hospitalization even in HFpEF

9. ACUTE DECOMPENSATED HEART FAILURE (ADHF)

Precipitants (Mnemonic: FAILURE)

Forgetting medications
Arrhythmia / Anemia
Ischemia / Infection
Life style (dietary indiscretion, excess salt/fluid)
Up in heart rate (uncontrolled AF)
Renal failure
Embolism (pulmonary)

Acute Management:

Position: Sit upright
Oxygen + BiPAP/CPAP for pulmonary edema
IV Furosemide (40-80 mg) - rapid diuresis
IV Nitrates (nitroglycerine/isosorbide dinitrate) - vasodilation, ↓ preload
Morphine (controversial - causes vasodilation, reduces anxiety; now less preferred)
Inotropes if cardiogenic shock: Dobutamine (positive inotrope), Dopamine
Vasopressors if refractory shock: Norepinephrine

10. PROGNOSIS - KEY FACTS

~50% mortality within 5 years of diagnosis
Annual sudden cardiac death risk 5-10x higher than general population
Poor prognostic markers: ↑ BNP, low Na+, low EF, NYHA class IV, renal dysfunction, QRS widening

11. HIGH-YIELD ONE-LINERS FOR NEET PG MCQs

Question type	Answer
Most common cause of HF	Ischemic heart disease (CAD/MI)
Most common cause of RHF	Left heart failure
Cor pulmonale =	RHF due to lung disease
Earliest symptom of LHF	Dyspnea on exertion
Gold standard investigation	2D Echocardiography
Best single biomarker	BNP / NT-proBNP
"Heart failure cells"	Hemosiderin-laden alveolar macrophages
"Nutmeg liver" seen in	Right heart failure (chronic congestive hepatomegaly)
S3 gallop heard in	Volume-overloaded/dilated ventricle (significant)
S4 gallop heard in	Stiff/non-compliant ventricle (HTN, HCM)
Drug that reduces mortality in HFrEF	ACEi, ARBs, β-blockers, ARNI, MRA, SGLT2i
Drug with NO mortality benefit	Diuretics, Digoxin
Drug contraindicated in HF	Verapamil, diltiazem, NSAIDs, thiazolidinediones
ARNI preferred over	ACE inhibitor (for HFrEF NYHA II-III)
β-blockers approved for HF	Carvedilol, Bisoprolol, Metoprolol succinate ONLY
ICD indication in HF	EF ≤35%, NYHA II-III, on GDMT
CRT indication	EF ≤35% + LBBB + QRS ≥150ms
Ivabradine used when	Sinus rhythm, HR >70, intolerant/max β-blocker dose
Spironolactone side effect to monitor	Hyperkalemia (stop if K+ >6 mmol/L)
Spironolactone male side effect	Gynecomastia (less with eplerenone)

Sources cited:

Goldman-Cecil Medicine, 26e - Chapter 45 (Heart Failure Epidemiology, Classification) and Chapter 46 (Management)
Robbins & Kumar Basic Pathology - Chapter 9 (Cardiac morphology and clinical features)
Braunwald's Heart Disease, 12e - Heart Failure Definition and Epidemiology
Lippincott Illustrated Reviews: Pharmacology - HF pharmacotherapy
Goodman & Gilman's Pharmacological Basis of Therapeutics - HF staging and drug mechanisms

This is a shared conversation. Sign in to Orris to start your own chat.